Ceftriaxone Dose for 292 lb STD Exposure
For a 292 lb (132 kg) patient with suspected sexually transmitted infection exposure, administer ceftriaxone 500 mg intramuscularly as a single dose, plus doxycycline 100 mg orally twice daily for 7 days if chlamydial coinfection has not been excluded.
Dosing Rationale
The most recent CDC guidance from 2020 updated the recommended ceftriaxone dose from 250 mg to 500 mg IM for uncomplicated gonorrhea at all anatomic sites (urogenital, anorectal, and pharyngeal) 1. This change was driven by antimicrobial stewardship principles and the rising azithromycin resistance, moving away from dual therapy with azithromycin to ceftriaxone monotherapy with doxycycline for chlamydial coverage 2.
Importantly, this 500 mg dose is weight-independent for adults - the patient's weight of 292 lb does not require dose adjustment. The FDA labeling confirms that standard adult dosing (1-2 g daily for serious infections, 250 mg for uncomplicated gonorrhea) requires no modification based on body weight alone 3. The pharmacokinetic data show that ceftriaxone achieves sustained bactericidal levels regardless of patient size within the adult population 3.
Treatment Algorithm
For Uncomplicated Urogenital/Rectal Gonorrhea:
- Ceftriaxone 500 mg IM once 1, 2
- PLUS doxycycline 100 mg PO twice daily × 7 days (if chlamydia not excluded) 1
For Pharyngeal Gonorrhea:
- Same regimen: Ceftriaxone 500 mg IM once 1
- Pharyngeal infections are harder to eradicate but respond to the 500 mg dose
- Test-of-cure required at 7-14 days for pharyngeal sites 4
If Ceftriaxone Unavailable:
- Cefixime 400 mg PO once PLUS azithromycin 1 g PO once
- Requires test-of-cure in 1 week 5
Critical Caveats
Do not increase the dose based on body weight alone. While older guidelines from 2002-2012 recommended 125-250 mg 6, 5, 6, the current standard is 500 mg for all adults regardless of weight. The evidence shows no treatment failures with standard dosing across weight ranges, and ceftriaxone's pharmacokinetics (95% protein binding, 5.8-8.7 hour half-life) provide adequate tissue penetration at standard doses 3.
Chlamydial coinfection occurs in 30-50% of gonorrhea cases, making empiric coverage essential unless specifically excluded by testing 1. Doxycycline is now preferred over azithromycin due to rising azithromycin resistance in N. gonorrhoeae (nearly 5% with elevated MICs by 2018) 2.
Geographic considerations: While fluoroquinolones were previously alternatives, widespread quinolone resistance makes them unreliable in most U.S. regions 6. Avoid ciprofloxacin/levofloxacin unless local susceptibility data support their use.
Monitoring
- No test-of-cure needed for uncomplicated urogenital/rectal gonorrhea if treated with recommended regimen 4
- Exception: Test-of-cure mandatory for pharyngeal gonorrhea at 7-14 days 4
- If symptoms persist after treatment, obtain culture with susceptibility testing and report to local health department 5
- Ensure partner notification and treatment within preceding 60 days 7
The 500 mg dose represents the optimal balance between efficacy (maintaining >99% cure rates), antimicrobial stewardship, and preventing resistance emergence, with no weight-based adjustment needed for this 292 lb patient 1, 2.